中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

30 records (took 0.048 seconds)

    Monoclonal antibody against FZD10 and use thereof
    1.
    发明授权
    Monoclonal antibody against FZD10 and use thereof 有权

    公开(公告)号：US11079386B2

    公开(公告)日：2021-08-03

    申请号：US16336846

    申请日：2017-10-04

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Yosuke Harada ,  Tatsuki Yokoseki ,  Yusuke Nakamura

    IPC: G01N33/574 ,  C07K16/28

    Abstract: The present invention relates to monoclonal antibodies against FZD10. Furthermore, the present invention provides methods for diagnosing FZD10-related diseases using such an antibody, methods for detecting a FZD10 protein, methods for determining drug efficacy after treatment with FZD10 inhibitors, and methods of screening for subjects in whom treatment with FZD10 inhibitors is highly effective, and provides diagnostic reagents containing such an antibody.

    Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
    2.
    发明授权
    Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides 有权
    表达MPHOSPH1或DEPDC1多肽的癌症疫苗

    公开(公告)号：US09545437B2

    公开(公告)日：2017-01-17

    申请号：US14667560

    申请日：2015-03-24

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Tomoaki Fujioka ,  Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Osawa ,  Midori Shida

    IPC: A61K39/00

    CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/54 ,  A61K2039/55566 ,  A61K2039/57 ,  A61K2039/572 ,  C07K7/06 ,  C07K14/4703

    Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, containing these peptides as an active ingredient. The peptides of the present invention can also be used as vaccines.

    Abstract translation: 本发明提供具有如SEQ ID NO：7,8,9,10,11,12,192,195,197,209,225,226,228,230,240,241,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,2 243,244,249,253,254或255，以及具有上述氨基酸序列的肽，其中1,2或几个氨基酸被取代，缺失或加入，其中肽具有细胞毒性T细胞诱导性 。 本发明还提供用于治疗或预防与MPHOSPH1和/或DEPDC1的过度表达相关的疾病的药物，例如， 含有这些肽作为活性成分的癌症。 本发明的肽也可以用作疫苗。

    TOPK PEPTIDES AND VACCINES INCLUDING THE SAME
    4.
    发明申请
    TOPK PEPTIDES AND VACCINES INCLUDING THE SAME 有权
    TOPK PEPTIDES和疫苗，包括它们

    公开(公告)号：US20140255437A1

    公开(公告)日：2014-09-11

    申请号：US14353261

    申请日：2012-10-25

    Applicant: c/o ONCOTHERAPY SCIENCE, INC.

    Inventor： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama

    IPC: A61K39/00 ,  C07K16/18 ,  C07K7/06

    CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K39/0005 ,  A61K2039/5154 ,  A61K2039/572 ,  C07K7/06 ,  C07K14/4748 ,  C07K16/18 ,  C07K16/40 ,  C07K2317/34 ,  C12N9/12 ,  C12N9/1205 ,  C12Y207/12002 ,  G01N33/505 ,  G01N33/574

    Abstract: The present invention provides isolated epitope peptides derived from TOPK and immunogenic fragments thereof have an ability to induce cytotoxic T lymphocytes (CTLs) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a TOPK-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have CTL inducibility. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical compositions of this invention find particular utility in either or both of the treatment and prevention of a number of cancers.

    Abstract translation: 本发明提供了源自TOPK的分离的表位肽，其免疫原性片段具有诱导细胞毒性T淋巴细胞（CTL）的能力，因此适用于癌症免疫治疗，更特别地，作为癌症疫苗。 本发明的肽包括包括TOPK衍生的氨基酸序列和其修饰形式的两种肽，其中一个，两个或几个氨基酸被取代，缺失，插入和/或添加，只要这些修饰版本具有CTL 诱导性。 还提供了编码任何前述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物组合物。 本发明的肽，多核苷酸和药物组合物在治疗和预防多种癌症中的任一者或两者中都具有特别的用途。

    HJURP peptides and vaccines including the same
    7.
    发明授权
    HJURP peptides and vaccines including the same 有权

    公开(公告)号：US09896492B2

    公开(公告)日：2018-02-20

    申请号：US15197278

    申请日：2016-06-29

    Applicant: OncoTherapy Science, Inc.

    Inventor： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC: A61K39/00 ,  C07K14/47 ,  C07K7/06 ,  C07K16/18 ,  A61K35/12 ,  A61K38/00

    CPC classification number: C07K14/4748 ,  A61K35/12 ,  A61K38/00 ,  A61K39/00 ,  C07K7/06 ,  C07K16/18

    Abstract: Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, Diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.

Patent Agency Ranking